oritavancin, dalbavancin, telavancin

[suntzu]

---

Members do not see this ad.

The last posts I could find on these agents were over 4 years old.

Interested whether anyone here has experience with any of these drugs yet. The current indications are still fairly restrictive [SSTI, telavancin apparently got HAP as well] but it sounds like they are actively pursuing data to support osteo. The advantages are obvious -- particularly for oritavancin with its lower cost, one time dosing (can you tell we've had a rep visit?). Cost is still a major consideration, ~$2600 for the "less-expensive" oritavancin, and it seems unclear whether it will even be paid for. However for certain outpatient situations it may make sense. I like dosing, monitoring for vancomycin. . .but this new class may end up taking over eventually. Very interesting MOA(s), PK, and spectrum. Any hospitals actually using any of these agents?


OK, honestly I don't care. Just wanted to get a little more 'pharmacy' on the pharmacy board.

 

[PolarPop]

Can't the hospital bill for the cost of the drug if the patient is placed on obs and given the infusion, watched for a few hours and sent home? If the insurance would cover it from an outpatient setting.

There is also a phase 3 trial of single vs two dose dalbavancin for SSTI right now but that would still be more expensive than oritavancin.